ClinicalTrials.gg
RecruitingNCT06561178Updated Aug 29, 2024

Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)

An observational study in Esophageal Squamous Cell Carcinoma, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2024-08-29.

Sponsored by Sun Yat-sen University · Observational

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
50
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Esophageal Squamous Cell Carcinoma by Sun Yat-sen University — 13 open to participants now, 19 under way, 4 of them phase 3. Esophageal Squamous Cell Carcinoma · Sun Yat-sen University.

Started
2024
with 3 others
Observational
Only one
of the 32
Primary completion
2027-12
later than 10 of 18 live
Registered
22nd of 32
by date

Among the 32 studies in Esophageal Squamous Cell Carcinoma by Sun Yat-sen University, this one is one of 4 that started in 2024, is the only observational one, reaches primary completion later than 10 of the 18 other live ones, and was the 22nd registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

13 of the 32 studies in Esophageal Squamous Cell Carcinoma by Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Esophageal Squamous Cell Carcinoma by Sun Yat-sen University, or all of them as a file.
02

Study summary

The goal of this observational study or is to explore the correlation between dynamic changes in postoperative circulating tumor DNA (ctDNA) and recurrence risk using a novel, tumor-informed ctDNA detection technique, thus laying the foundation for further promoting ctDNA detection to guide postoperative adjuvant therapy decisions. This study focuses on patients with esophageal squamous cell carcinoma who did not achieve pCR following neoadjuvant therapy combined with surgical resection. The main question it aims to answer is:

Is there a correlation between postoperative ctDNA changes and tumor recurrence?

Participants will be asked to undergo postoperative ctDNA detection.

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma

Keywords

  • ctDNA
  • recurrence detection
  • esophageal squamous cell carcinoma
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with esophageal squamous cell carcinoma who have not achieved pCR following neoadjuvant chemoradiotherapy and surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Operable locally advanced esophageal squamous cell carcinoma;
  2. Have received chemoradiotherapy ± immunotherapy and have not achieved pCR after R0 resection;
  3. Can tolerate postoperative adjuvant immunotherapy;
  4. Sufficient baseline tumor tissue and blood samples available for NGS testing;
  5. (ECOG) performance status score of 0-1;
  6. Consents to and is capable of complying with the scheduled study visits, treatment plans, laboratory tests, and other study procedures
  7. Expected postoperative survival time of ≥ 6 months.

Exclusion criteria

Exclusion Criteria:

  1. Concurrent other malignant tumors;
  2. Lack of a detailed histopathological diagnostic report for determining the nature of the lesion;
  3. Severe and/or poorly controlled medical conditions that, in the investigator's judgment, could affect participation or interfere with study results;
  4. Any social/psychological issues that, in the investigator's judgment, make the patient unsuitable for participation;
  5. Unable to undergo long-term, regular postoperative follow-up at the current medical institution;
  6. Unwilling or unable to comply with the study protocol.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
50 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Interventions

  • Diagnostic testmolecular residual disease detection

    ctDNA detection

06

What researchers measure

Primary outcomes

  1. Correlation between the recurrence of patients and the quantitative measurement of circulating tumor DNA (ctDNA) concentration.

    Correlation were evaluated based on the sensitivity and specificity of ctDNA in predicting recurrence.The sensitivity and specificity were determined by evaluating the association between positive ctDNA and tumor recurrence.

    Time frame: 3 years

Secondary outcomes

  1. Postoperative molecular residual disease (MRD) positive rate

    Time frame: 3 years

  2. Correlation between ctDNA detection and postoperative adjuvant therapy.

    The ctDNA assay was employed to inform postoperative adjuvant therapy, with the objective of determining its potential to enhance patient prognosis.

    Time frame: 3 years

  3. correlation between patients' prognosis and landmark MRD status

    The sensitivity and specificity were determined by evaluating the association between positive landmark MRD status and patients' prognosis.

    Time frame: 3 years

  4. 2-year disease-free survival

    Time frame: 2 years

  5. 3-year disease-free survival

    Time frame: 3 years

  6. 5-year disease-free survival

    Time frame: 5 years

  7. 2-year overall survival

    Time frame: 2 years

  8. 3-year overall survival

    Time frame: 3 years

  9. 5-year overall survival

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2024 (actual). Primary completion is estimated for Dec 2027, 40 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2024
First posted
Aug 19, 2024
StartActual
Aug 26, 2024
Primary completionEst.
Dec 30, 2027
CompletionEst.
Jun 1, 2028
Last update
Aug 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06561178
Responsible party
Yang Hong (Prof., Sun Yat-sen University) — Principal investigator
First posted
Aug 19, 2024
Start date
Aug 26, 2024
Primary completion
Dec 30, 2027 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Aug 29, 2024

Study contacts

Hong Yang, MD
Contact
yanghong@sysucc.org.cn
86-020-87343932 ext. 020-87343932
Hong Yang, M.D.;Ph.D.
principal investigator · Sun Yat-sen University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion